In the Press
Thursday, October 18, 2018The president has entirely too many lawyers (and not just this president) White House Watch
Wednesday, October 17, 2018Report re-energizes push to end solitary confinement in state NJTV
Tuesday, October 16, 2018Could an Ex-Convict Become an Attorney? I Intended to Find Out.—A Commentary by Reginald Dwayne Betts ’16 The New York Times Magazine
Tuesday, October 16, 2018Literary group sues Trump, alleges free speech stifling The Associated Press
Tuesday, November 21, 2017
James Geraghty ’80 Appointed Chairman of Pieris Pharmaceuticals Board
Pieris Pharmaceuticals Inc announced that James Geraghty ’80 has been appointed Chairman of the Board of Directors.
Pieris Pharmaceuticals is a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(R) technology platform for cancer, respiratory and other diseases. The President and CEO of Pieris Pharmaceuticals, Stephen S. Yoder, said, "Jim's proven track record of success and deep experience in the biopharmaceutical industry will be instrumental in guiding Pieris through its next chapter of development, particularly as we advance PRS-343, our proprietary lead immuno-oncology program, into later stage development."
Jim Geraghty has served as member of the Pieris Board of Directors since May 2017 and is an industry leader with thirty years of strategic and leadership experience, including more than twenty years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty was most recently an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund, and previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent twenty years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Juniper Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, Mr. Geraghty holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.